We first confirmed the antitumor effect of the antimouse VEGFR2 antibody DC101 by inhibiting angiogenesis using a xenograft mouse model transplanted with AFP-positive/EpCAM-positive human HCC cells. This evidence concerns the gene AFP and hepatocellular carcinoma.